Peptides+antibiotic combination may result in a more effective treatment for leishmaniasis

October 16, 2020

Leishmaniasis is caused by the protozoan Leishmania parasites which are transmitted by the bite of an infected sandfly. Although in rich countries this disease mainly affects dogs, in other countries it can wreak havoc on the health of humans, causing anything from ulcers to damage to the bone marrow, liver or spleen, all which could be fatal. The WHO estimates that there are currently over one billion people living in areas in which leichmaniasis is endemic and that there are over one million new cases each year. There is therefore an urgent need to find new, efficient and selective alternatives to leishmaniasis chemotherapy which can reduce the adverse side effects of existing drugs such as paromomycin and miltefosine.

Lecturers Rosa Maria Ortuño and Ona Illa from the UAB Department of Chemistry were in charge of coordinating a multidisciplinary research into finding new anti-Leishmania therapies. Also involved in the study were the groups of lecturer Jean-Didier Maréchal, from the same department, and of lecturer Carme Nogués, from the UAB Department of Cell Biology, Phyisology and Immunology, as well as researchers Luis Rivas from the CIB Margarita Salas - CSIC (Madrid) and Míriam Royo from the IQAC - CSIC (Barcelona).

The study consisted in the preparation and biological evaluation of new cell-penetrating peptides (CPPs) which, with an antibiotic conjugation, serve as a vehicle or vector for the drug, enabling it to enter the parasite's cell membrane and be released inside, thus causing its death. The result is greater effectiveness, while at the same time a lower number of oral doses of the drug are needed. In addition, the synthesised CPPs are not toxic for mammal cells, but are for the Leishmania. "Although the idea of using CPPs in the treatment of leishmaniasis is not unknown, the importance of this study lies in its high cell-penetrating capacity and the selectivity (mammal vs parasite cells) of the new synthesised and studied peptides", explains Rosa Maria Ortuño.

In particular, the research has served to study peptides made up of non-protein amino acids with a covalent conjugate of doxorubicin (Dox), a drug which is also used in cancer treatments. While Dox in its free form is not active when incubated with Leishmania because it is not capable of penetrating its interior, the Dox-PPC conjugate has demonstrated to be toxic in very low concentrations. Its cell-penetrating capacity has been rationalised through molecular modelling studies. The results are highly promising, and "a great deal of research is still needed before thinking about new drugs, but we are now a little bit closer of our objective", concludes Ortuño.
-end-


Universitat Autonoma de Barcelona

Related Leishmaniasis Articles from Brightsurf:

Peptides+antibiotic combination may result in a more effective treatment for leishmaniasis
A combination of peptides and antibiotics could be key to eliminating the parasite causing leishmaniasis and avoiding the toxicity to people and animals caused by current drugs.

Chemical offers new hope of finding treatments for neglected tropical diseases
Scientists say they are a step closer to developing a drug to kill the trypanosome parasite that causes human African trypanosomiasis, otherwise known as sleeping sickness, paving the way for a potential cure.

A study investigating genetic mechanisms underlying resistance to leishmaniasis
The study was conducted in Brazil and mapped the genes that are activated when mice resistant to Leishmania are infected.

How sand fly mating habits are helping tackle tropical disease in £2.5 million project
The tropical disease Leishmaniasis is being tackled by catching female sand flies who carry the parasite that causes the disease in both dogs and humans.

Predicting treatment outcome for leishmaniasis
The current first-line treatment for leishmaniasis, a skin disease that can cause disfiguring ulcers, is grueling and frequently fails.

New species of parasite is identified in fatal case of visceral leishmaniasis
Phylogenomic analysis shows that pathogen isolated in Brazilian hospital does not belong to the genus Leishmania.

Emerging parasitic disease mimics the symptoms of visceral leishmaniasis in people
A new study suggests that transmission of a protozoan parasite from insects may also cause leishmaniasis-like symptoms in people.

How visceral leishmaniasis spread through central-Southern Brazil
The protozoan disease visceral leishmaniasis (VL) has recently expanded to places where it had not previously been reported and has expanded its geographic distribution within countries where it was already endemic.

Researchers compare visceral leishmaniasis diagnostic tests
Accurate and timely diagnosis of the tropic disease visceral leishmaniasis (VL) is one of the pillars for reducing VL deaths.

Biocompound from Atlantic Rainforest combats leishmaniasis and Chagas disease
Researchers find that substances synthesized from plant species endemic to the biodiversity hotspot can kill the parasites that cause these neglected diseases.

Read More: Leishmaniasis News and Leishmaniasis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.